NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA). Validation means that the EMA has confirmed that the application is complete and the agency is beginning its review procedure. Pfizer studied tofacitinib for moderate-to-

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center’s Corporate Citizenship Award in the Best International Ambassador category for Pfizer’s Global Health Partnerships program. The “Citizens” Awards honor excellence in corporate citizenship and civic leadership for initiatives in both the United States and across the world. “The essence of a successful corporate social responsibility program is when it becomes a model that other c

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the European Commission has approved Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. 1,2,3 “A diagnosis of TTR-FAP, usually made in patients during their mid-life years, impacts both the physical and emotional well-

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, yesterday, kicked off a nationwide effort to make a difference in communities. The cold and flu brand is putting a twist on its tagline – “The Right Relief for the Real Problem,” and providing literal relief in congested places across the US. In its first relief stop, The Advil® Congestion Relief Project unveiled a new library at P.S. 130 in the Bronx. Yankee fan favorite Brett Gardner helped unve

NEW YORK--(BUSINESS WIRE)--Kathryn Joosten, two-time Emmy® Award-winning actress and star of Desperate Housewives and The West Wing, is opening up about her 10-year battle with lung cancer as part of a new national campaign, Lung Cancer Profiles. Lung Cancer Profiles aims to reduce the stigma associated with lung cancer by educating about the diversity of the disease inside and out. The campaign, created by Pfizer Oncology in collaboration with the nation’s leading lung cancer advocacy groups, a

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30. The apixaban arm had a 13 percent lower rate

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency. The study met its primary endpoint, as treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urinary urgency episodes overnight during sleep hours after 12 weeks of treatment.

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML),1 inotuzumab in non-Hodgkin lymphoma (NHL),2 as well as the first presentation of clinical data for PF-04449913,3 which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.4 In addition, ongoing investigator-initiated research on gemtuzumab ozogamicin (Mylotarg) will be presented in

THOUSAND OAKS, Calif. & NEW YORK--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate (MTX) in Period one and were randomized to continue on ENBREL plus MT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):     ($ in millions, except per share amounts)   Third-Quarter(4)   Year-to-Date(4) 2011   2010   Change 2011   2010   Change Reported Revenues $ 17,193 $ 15,995 7 % $ 50,679 $ 49,703 2 % Adjusted Income(1) 4,820 4,352 11 % 14,354 14,141 2 % Adjusted Diluted EPS(1) 0.62 0.54 15 % 1.81 1.75 3 % Reported Net Income(2) 3,738 866 * 8,570 5,367 60 % Reported Diluted EPS(2) 0.48 0.11 * 1.08 0.66 64 %                                       See end of te